Navigation Links
Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma
Date:6/18/2013

LONDON, June 18, 2013 /PRNewswire/ --

Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage of BioAlliance Pharma (BIO.PA), a French biopharmaceutical company developing and marketing products for orphan oncology and oncology supportive care indications.

     (Logo: http://photos.prnewswire.com/prnh/20130417/608168)

Edison has today published a comprehensive report examining the investment merits of BioAlliance Pharma, focusing in particular on the potential of its lead product, Livatag, for hepatocellular carcinoma. Livatag is in a Phase III study, RELIVE, which is expected to render final results in 2016. The report identifies a number of earlier catalysts, including the potential partnering of Sitavig for cold sores, which was approved by the FDA in April 2013. Edison has valued BioAlliance at €109m based on a risk-adjusted net present value model.

For the full report see: http://www.edisoninvestmentresearch.com/research/company/bioalliance-pharma

The launch of coverage on BioAlliance is part of a programme of research initiations on healthcare companies worldwide. Edison provides research coverage on more than 130 healthcare companies in Europe, North America and Australia. Edison has pioneered a scientific, detail-oriented approach to analysing companies in the healthcare sector that is delivered in a concise and non-promotional manner. It aims to inform investors, while providing a realistic assessment of the competitive strengths and threats to key drug development programmes. All facts are carefully sourced and the analysis is underpinned by comprehensive and rigorous financial models. Edison's reports provide an overall company valuation without any specific stock recommendation.

All reports published by Edison are available to download free of charge from its website http://www.edisongroup.com.

About Edison Investment Research

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Berlin, Sydney and Wellington. Edison is authorised and regulated by the Financial Services Authority (http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

About BioAlliance Pharma

Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products for speciality markets, especially in the hospital setting and for orphan or rare diseases. Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation with patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

For more information please contact:
Luke Polonieki    
Edison Investment Research          
+44-(0)-20-3077-5700
healthcare@edisongroup.com


'/>"/>
SOURCE Edison Investment Research and BioAlliance Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. CellHealth Institute is Named 2013 Edison Award Winner
2. Stanford scientists spark new interest in the century-old Edison battery
3. Cellular Dynamics International Expands MyCell Products Line with Disease Models, Genetic Engineering Patents
4. Julabo USA Inc. Expands Its Line of Compact and Economic Cooling Circulators
5. Rocky Mountain Biologicals Expands Custom Serum Filtration Facility
6. GenoSpace Expands Its Management Team by Appointing Daniel Meyer as Chief Financial Officer
7. GLM Displays Expands Its Line of Formulate Fabric Displays with the Vibe 10ft Display
8. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
9. Leading Chemical Manufacturer Expands Biobased Offering through Unique Distribution of Proven Green Spill Absorbent
10. Defying Industry Trends, BBK Worldwide Expands Ownership From Within
11. Abacus International Expands Annual Partnership With HealthEconomics.Com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2018)... ... , ... The American Medical Informatics Association (AMIA) is proud to announce the ... the AMIA 2018 Annual Symposium , taking place Nov. 3 – 7, in ... more than 700 submissions. The AMIA Signature Awards program provides an opportunity for AMIA ...
(Date:10/5/2018)... ... October 04, 2018 , ... Power T ... Spine Technology Award from Orthopedics This Week during the 2018 National Association of ... Handle is a surgical instrument that delivers operating room efficiencies through increased speed ...
(Date:10/2/2018)... ... October 02, 2018 , ... ... today announced a new out-of-the-box integration of the Genedata Bioprocess ® ... and laboratory equipment supplier. This enables the automatic import of raw instrument ...
(Date:9/28/2018)... ... September 28, 2018 , ... ... to increase the availability of the GlycoMark test, the only FDA-cleared blood test ... the partnership, PMLS will promote and offer the GlycoMark test to its network ...
Breaking Biology Technology:
(Date:10/13/2018)... (PRWEB) , ... October 12, 2018 , ... ... announced it will host a booth at premier packaging event PACK EXPO International ... the Packaging Machinery Manufacturers Institute (PMMI), of which HOLLOWAY AMERICA is a member. ...
(Date:10/11/2018)... ... October 09, 2018 , ... LaunchBio, ... science and biotechnology companies, announced today that it will host a forum ... investment philosophies, explain their fund and deal structures, and describe how they ...
(Date:10/11/2018)... NEW YORK (PRWEB) , ... October 10, 2018 ... ... human technology is enabling newly diagnosed breast cancer patients to learn about their ... health outcomes for women with triple negative breast cancer (TNBC), and was developed ...
Breaking Biology News(10 mins):